G.J.D. Hengstman

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Autoantibody profiles in the sera of European patients with myositis

R M Brouwer, G.J.D. Hengstman, W.T.M. Vree Egberts et al. · Annals of the Rheumatic Diseases · 2001 · 405 citations · Full text

Life Sciences, Immunology, Internal Medicine +16

Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy

G.J.D. Hengstman, H. J. ter Laak, W.T.M. Vree Egberts et al. · Annals of the Rheumatic Diseases · 2006 · 335 citations · Full text

Medicine, Immunology, Pathology +17

Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations

G.J.D. Hengstman, F.H.J. van den Hoogen, Pilar Barrera et al. · European Neurology · 2003 · 157 citations

Medicine, Immunology, Pharmacotherapy +17

Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies.

J. Van der Pas, G.J.D. Hengstman, H. J. ter Laak et al. · PubMed · 2004 · 146 citations

Life Sciences, Immunology, Pathology +13